title: Decorin derived antiangiogenic peptide LRR5 inhibits endothelial cell migration by interfering with VEGF-stimulated NO release.
abstract: Excessive angiogenesis plays critical roles in many human diseases including cancer. We have previously shown that human decorin derived 26 amino acids peptide Leucine Rich Repeat 5 (LRR5) inhibits multiple aspects of angiogenesis including vascular endothelial growth factor (VEGF) stimulated migration of endothelial cells (ECs). In this study, we have characterized the molecular mechanism of LRR5 which reveals that its anti-migratory effect on ECs is mediated by inhibiting VEGF-stimulated endothelial nitric oxide synthase (eNOS) activation and nitric oxide (NO) release. LRR5 carried out this function through signaling pathways that involves PI3 kinase and Akt, but not ERK. This anti-NO release effect is mediated by the C-terminal 13 amino acids of LRR5, correlating with the anti-migratory function of this region.
authors: Department of Biological Sciences, National University of Singapore, BLK S2, 05-04, Science Drive 4, Singapore 117543, Singapore. fanhuapeng@nus.edu.sg
authors: Huapeng
authors: H
authors: Fan
authors: K N
authors: KN
authors: Sulochana
authors: Yap-Seng
authors: YS
authors: Chong
authors: Ruowen
authors: R
authors: Ge
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D002465:Cell Movement / Q000187:drug effects*; D002478:Cells, Cultured; D058575:Decorin; D042783:Endothelial Cells / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D004789:Enzyme Activation / Q000187:drug effects; D016326:Extracellular Matrix Proteins / Q000737:chemistry*; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D006801:Humans; D000090263:Leucine-Rich Repeat Proteins; D008954:Models, Biological; D009569:Nitric Oxide / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D010768:Phosphoserine / Q000378:metabolism; D011506:Proteins / Q000494:pharmacology*; D011509:Proteoglycans / Q000737:chemistry*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology*
chemical_list: D020533:Angiogenesis Inhibitors; D058575:Decorin; D016326:Extracellular Matrix Proteins; D048049:Extracellular Signal-Regulated MAP Kinases; D000090263:Leucine-Rich Repeat Proteins; D009569:Nitric Oxide; D052250:Nitric Oxide Synthase Type III; D010455:Peptides; D019869:Phosphatidylinositol 3-Kinases; D010768:Phosphoserine; D011506:Proteins; D011509:Proteoglycans; D051057:Proto-Oncogene Proteins c-akt; D042461:Vascular Endothelial Growth Factor A; C546878:DCN protein, human; C467484:VEGFA protein, human